Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth

BUFFALO, N.Y., Jan. 21, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.  The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, together with the University of Florida Shands Cancer Center.

In a poster presentation, CureFAKtor Chief Scientific Officer Dr. William Cance and Senior Scientist Dr. Elena Kurenova reported that the study pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells.  CureFAKtor's lead compound, CFAK-C4, reduced tumor growth in vivo in mouse pancreatic cancer cells by up to 60 percent, and CFAK-C4 combined with chemotherapy drug gemcitabine had a synergistic effect and led to 80 percent pancreatic cancer tumor reduction.  

The study also found that CFAK-C4 combined with gemcitabine had a prolonged effect on pancreatic tumor growth.  Two weeks after treatment, the tumor size in the previously treated group was approximately 75 percent smaller than the tumor in the control group. The researchers concluded that targeting FAK with small molecule inhibitors can be effectively used to develop potential oral-based cancer therapies.

"Focal Adhesion Kinase protein binding inhibitors, such as CFAK-C4, represent a promising area of research as FAK is expressed at extremely high levels in solid cancer tumors and serves as a survival mechanism by signaling tumor growth, invasion and metastasis," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals.  "CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumor cancers in that its unique mechanism of action disrupts the signaling of specific protein to protein binding between FAK and tumors."

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options.

About Focal Adhesion Kinase (FAK)Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.  

About CureFAKtor PharmaceuticalsCureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer. CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute.  CureFAKtor is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy, the current standard of care for pancreatic cancer, in 2012.  Additional information about the company may be found at

Forward-Looking Safe Harbor Statement:This press release contains forward-looking statements for CureFAKtor Pharmaceuticals that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.  Media ContactRx Communications Group, LLCEric GoldmanVice President, Public

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. Amylin Pharmaceuticals to Webcast Year-End Financial Results
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
5. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
6. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
7. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
8. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
10. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
11. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock ... concert posters. This is one of Joplin's most famous and beautiful concert posters. The ... of Michigan in Ann Arbor. The According to Hawley, "It is hard to believe ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
Breaking Medicine News(10 mins):